The first SmartGenRx product is a polypill – combination medicine for cardiovascular disease. The product is constituted with class leading, commonly used cardiovascular medicines that have each been proven to be highly effective and safe in large clinical trials.

This product has the potential to deliver substantial benefits at a fraction of the cost of existing treatments for heart disease or stroke. Research shows that when people take these combinations there may be a 40% improvement in adherence to recommended medicines.